ClinicalTrials.gg
RecruitingNCT07340268Updated Feb 4, 2026

The Effects of Transcranial Current Stimulation on Insomnia

An interventional study of transcranial current stimulation and Sham stimulation in Insomnia, Psychophysiological, sponsored by Zan Wang. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Zan Wang · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 198 studies in Sleep Initiation and Maintenance Disorders with a site in China — 82 open to participants now, 88 under way, 2 of them phase 3. Sleep Initiation and Maintenance Disorders · China.

Planned enrollment
75th of 162
100 · median 88
Started
2026
with 27 others
No phase
123 of 198
56 open now
Primary completion
2026-11
later than 48 of 87 live
Registered
167th of 198
by date

Among the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, this one is the 75th largest by planned enrollment of the 162 interventional ones that give a count, is one of 28 that started in 2026, is one of 123 with no phase, reaches primary completion later than 48 of the 87 other live ones, and was the 167th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

82 of the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China are open now. Recruiting first, the newest first:

76 more — sign in →

All 82 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, or all of them as a file.
02

Study summary

Effect of transcranial current stimulation on insomnia disorder

Read the detailed description

Insomnia disorder represents a prevalent clinical challenge, transcranial current stimulation has emerged as a promising noninvasive therapeutic approach; however, its specific effects on neurophysiological mechanisms underlying sleep-related brain structure and functional change, and neurobiological change remain unclear.

03

Conditions studied

  • Insomnia, Psychophysiological
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of insomnia disorder
  • Cooperate to complete the questionnaire surveys

Exclusion criteria

Exclusion Criteria:

  • Presence of mental disorders
  • Current use of central nervous system stimulants
  • Use of analgesics,sedatives or hypnotic medications, theophylline preparations, medications
  • Alcohol abuse or regular alcohol consumption
  • Diagnosis of other sleep disorders, including obstructive sleep apnea, rapid eye movement sleep behavior disorder, or restless legs syndrome
  • Sleep disorders secondary to organic diseases, such as epilepsy, diabetes, or renal failure
  • Shift work or irregular work schedules that disrupt normal circadian rhythms
  • Use of medications affecting central nervous system function within the past one month
  • Recent sleep-related confounding behaviors within the past two weeks, including staying up late, alcohol consumption, or smoking
  • Presence of organic brain lesions on head MRI and to MRI examination
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    active transcranial current stimulation

    14 daily 20-min, 1.1-mA sessions of active or sham transcranial current stimulation, at the beginning and end of treatment, there is a 30 second period of current fading in and out

    Device: transcranial current stimulation

  • Sham comparator
    sham transcranial current stimulation

    only wore the device and had no stimulation

    Device: Sham stimulation

Interventions

  • Devicetranscranial current stimulation

    consecutive daily 20-min, 1.1-mA sessions

  • DeviceSham stimulation

    only wore the device and had no stimulation

06

What researchers measure

Primary outcomes

  1. Change in global blood-oxygen-level-dependent (gBOLD) signal amplitude

    The amplitude of the global blood-oxygen-level-dependent (gBOLD) signal was derived from resting-state functional MRI and reflects the overall magnitude of spontaneous brain activity. Unit of Measure: Z-score

    Time frame: 2 weeks and 3 months

  2. Change in resting-state functional connectivity strength

    Resting-state functional connectivity strength was calculated as the correlation coefficient between predefined brain regions based on functional magnetic resonance imaging data.

    Time frame: 2 weeks and 3 months

  3. Change in amplitude of low-frequency fluctuations

    Amplitude of low-frequency fluctuations was calculated from resting-state fMRI to quantify spontaneous neural activity.

    Time frame: 2 weeks and 3 months

  4. Change in regional homogeneity

    Regional homogeneity was used to assess the synchronization of local spontaneous brain activity

    Time frame: 2 weeks and 3 months

  5. Change in phase difference of dynamic cerebral autoregulation

    Dynamic cerebral autoregulation was assessed using the phase difference between cerebral blood flow velocity and arterial blood pressure fluctuations. Larger phase differences indicate better autoregulatory function.

    Time frame: 2 weeks and 3 months

  6. Change in gain of dynamic cerebral autoregulation

    Gain represents the magnitude of cerebral blood flow velocity changes in response to blood pressure fluctuations, with lower gain values indicating more effective autoregulation.

    Time frame: 2 weeks and 3 months

Secondary outcomes

  1. the score of Insomnia Severity Index scale

    The total score ranges from 0 to 28, and a higher score indicates higher levels of insomnia severity. A score of 8 or greater is the cut point for clinically possible insomnia

    Time frame: 2 weeks and 3 months

  2. the score of 14-item Hamilton anxiety rating scale

    The total score ranges from 0 to 56, and a higher score indicates higher levels of anxiety symptoms. A score of 7 or greater is the cut point for clinically possible anxiety

    Time frame: 2 weeks and 3 months

  3. the score of 17-item Hamilton depression rating scale

    tThe total score ranges from 0 to 52, and a higher score indicates higher levels of depression symptoms. A score of 7 or greater is the cut point for clinically possible depression symptom

    Time frame: 2 weeks and 3 months

  4. Change in plasma corticotropin-releasing factor (CRF) level

    Plasma corticotropin-releasing factor (CRF) concentration was measured as a biomarker of hypothalamic-pituitary-adrenal (HPA) axis activity. Higher levels indicate increased neuroendocrine stress response. Unit of Measure: pg/mL

    Time frame: 2 weeks and 3 months

  5. Change in plasma cortisol level

    Plasma cortisol concentration was assessed as an indicator of hypothalamic-pituitary-adrenal (HPA) axis function. Higher levels reflect increased physiological stress response. Unit of Measure: μg/dL

    Time frame: 2 weeks and 3 months

  6. Change in serum interleukin-6 level

    Serum interleukin-6 concentration was measured as a marker of systemic inflammation. Higher levels indicate greater inflammatory activity. Unit of Measure: pg/mL

    Time frame: 2 weeks and 3 months

  7. Change in serum brain-derived neurotrophic factor level

    Serum brain-derived neurotrophic factor concentration was measured as a biomarker associated with neuroplasticity and neuronal function. Higher levels indicate enhanced neurotrophic activity. Unit of Measure: pg/mL

    Time frame: 2 weeks and 3 months

  8. Change in total sleep time (TST) measured by polysomnography

    Time frame: 2 weeks and 3 months

  9. Change in sleep onset latency (SOL) measured by polysomnography

    Time frame: 2 weeks and 3 months

  10. Change in wake after sleep onset (WASO) measured by polysomnography

    Time frame: 2 weeks and 3 months

07

Study locations

1 of 2 sites recruiting
08

References and documents

Publications

  • Zhang Y, Sun Q, Zhang X, Li W, Wang Y, Cai L, Wang Z. Transcranial direct current stimulation improves reduced global BOLD-CSF coupling in patients with insomnia disorder and comorbid anxiety: a resting-state functional MRI study. BMC Psychiatry. 2026 Jun 17. doi: 10.1186/s12888-026-08304-6. Online ahead of print. PubMed 42310658 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Nov 2026, 10 months after the start.

Of 1,219 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 10 months is below that.

Counting every sponsor, half of 1,297 studies reached it within 15 months; a quarter within 6 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2026
First posted
Jan 14, 2026
StartActual
Jan 18, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07340268
Lead sponsor
Zan Wang
Responsible party
Zan Wang (Sleep Center Director, The First Hospital of Jilin University) — Sponsor-investigator
First posted
Jan 14, 2026
Start date
Jan 18, 2026
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 4, 2026

Study contacts

Zan Wang, MD, PhD
Contact
wangzan@jlu.edu.cn
+86 88782678

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion